Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1.
暂无分享,去创建一个
[1] G. Stone. Primary angioplasty versus “earlier” thrombolysis—time for a wake-up call , 2002, The Lancet.
[2] P. Touboul,et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study , 2002, The Lancet.
[3] J. Reiner,et al. How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction. , 2002, American heart journal.
[4] E. Antman,et al. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. , 2002, Journal of the American College of Cardiology.
[5] R. Califf,et al. Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. , 2002, American heart journal.
[6] H. Heidbuchel,et al. Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial , 2002, Circulation.
[7] H. White,et al. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial , 2001, The Lancet.
[8] Assent investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.
[9] P. Armstrong,et al. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. , 2001, Circulation.
[10] P. Armstrong,et al. Bolus fibrinolysis: risk, benefit, and opportunities. , 2001, Circulation.
[11] J. Rumsfeld,et al. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. , 2000, JAMA.
[12] H. White. Thrombolytic therapy in the elderly , 2000, The Lancet.
[13] InTIME-II Investigators,et al. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. , 2000, European heart journal.
[14] F. Van de Werf,et al. Polyethylene Glycol–Derivatized Cysteine-Substitution Variants of Recombinant Staphylokinase for Single-Bolus Treatment of Acute Myocardial Infarction , 2000, Circulation.
[15] A. Skene,et al. Survival Outcomes 1 Year After Reperfusion Therapy With Either Alteplase or Reteplase for Acute Myocardial Infarction: Results From the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial , 2000, Circulation.
[16] M. Simoons,et al. Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double-blind study. , 2000, European heart journal.
[17] M. Schwaiger,et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. , 2000, The New England journal of medicine.
[18] S. Yusuf,et al. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis , 2000, The Lancet.
[19] H A Feldman,et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial. , 2000, JAMA.
[20] C M Gibson,et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. , 2000, JAMA.
[21] E. Antman,et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. , 2000, Circulation.
[22] L. Morrison,et al. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. , 2000, JAMA.
[23] N. Powe,et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. , 2000, Circulation.
[24] P. Armstrong,et al. Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). , 2000, American heart journal.
[25] E. Topol,et al. Recognition of the importance of embolization in atherosclerotic vascular disease. , 2000, Circulation.
[26] E. Antman,et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. , 2000, Circulation.
[27] S. Greenhouse,et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial , 1999 .
[28] D. Freimark,et al. The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. , 1999, Journal of the American College of Cardiology.
[29] C. Bode,et al. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. , 1999, Circulation.
[30] F. Neumann,et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. , 1999, Journal of the American College of Cardiology.
[31] J S Alpert,et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) , 1999, Circulation.
[32] F. Werf. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.
[33] H. White,et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. , 1999, The New England journal of medicine.
[34] R. Califf,et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. , 1999, Circulation.
[35] P. Carmeliet,et al. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. , 1999, Circulation.
[36] E. Antman,et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.
[37] J. Ferrières,et al. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": one-year results from a nationwide French survey. , 1999, Circulation.
[38] C. Gibson,et al. Primary Angioplasty Compared with Thrombolysis: New Issues in the Era of Glycoprotein IIb/IIIa Inhibition and Intracoronary Stenting , 1999, Annals of Internal Medicine.
[39] E. Braunwald,et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. , 1999, American heart journal.
[40] J. Hirsh,et al. New antithrombotic agents , 1999, The Lancet.
[41] A. Siegbahn,et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). , 1999, Journal of the American College of Cardiology.
[42] E. Antman,et al. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. , 1999, Journal of the American College of Cardiology.
[43] R. Giugliano,et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.
[44] J. López-Sendón,et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. , 1998, Circulation.
[45] J. Gurwitz,et al. Risk for Intracranial Hemorrhage after Tissue Plasminogen Activator Treatment for Acute Myocardial Infarction , 1998, Annals of Internal Medicine.
[46] F. Werf. A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction , 1998 .
[47] E. Topol. A comparison of reteplase with alteplase for acute myocardial infarction. , 1998, The New England journal of medicine.
[48] R. Gibbons,et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. , 1998, JAMA.
[49] S. Usuda,et al. YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi. , 1998, Japanese journal of pharmacology.
[50] E. Topol,et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.
[51] V. Fuster,et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. , 1998, Journal of the American College of Cardiology.
[52] C. Davies,et al. Failed coronary thrombolysis , 1998, The Lancet.
[53] Yuan Zhang,et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. , 1998, Circulation.
[54] D. Collen. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent , 1998, Nature Medicine.
[55] W. Fennell,et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. , 1998, Journal of the American College of Cardiology.
[56] E. Topol. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. , 1998, Circulation.
[57] Anderson Jl. Why does thrombolysis fail? Breaking through the reperfusion ceiling. , 1997 .
[58] R. Dietz,et al. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction. , 1997, Journal of the American College of Cardiology.
[59] R. Collins,et al. Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO) , 1997 .
[60] F. Van de Werf,et al. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. , 1997, American heart journal.
[61] R. Califf,et al. Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction , 1997 .
[62] S. Hosoda,et al. A Prospective, Randomized, Double-Blind Multicenter Trial of a Single Bolus Injection of the Novel Modified t-PA E6010 in the Treatment of Acute Myocardial Infarction: Comparison With Native t-PA , 1997 .
[63] U. Rosenschein,et al. Analysis of coronary ultrasound thrombolysis endpoints in acute myocardial infarction (ACUTE trial). Results of the feasibility phase. , 1997, Circulation.
[64] P. Fitzgerald,et al. Catheter-based ultrasound thrombolysis. , 1997, Circulation.
[65] W. Klein,et al. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. , 1997, The American journal of cardiology.
[66] T. Investigators,et al. A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .
[67] E. Braunwald,et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.
[68] E. Raftery,et al. The association between cardiac events and myocardial ischaemia following thrombolysis in acute myocardial infarction and the impact of carvedilol. , 1996, European heart journal.
[69] Eric Boersma,et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.
[70] W. Weaver,et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. , 1996, Circulation.
[71] Y. Taniyama,et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. , 1996, Circulation.
[72] T. Aufderheide,et al. Test of the acute cardiac ischemia time-insensitive predictive instrument (ACI-TIPI) for prehospital use. , 1996, Annals of emergency medicine.
[73] L. Barrios,et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. , 1995, Circulation.
[74] R. Wilcox. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence: International Joint Efficacy Comparison of Thrombolytics , 1995 .
[75] R. Wilcox,et al. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence International Joint Efficacy Comparison of Thrombolytics , 1995, The Lancet.
[76] J. Kalbfleisch,et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. , 1995, Circulation.
[77] B. Sobel. Intracranial bleeding, fibrinolysis, and anticoagulation. Causal connections and clinical implications. , 1994, Circulation.
[78] K. Wegscheider,et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. , 1994, Journal of the American College of Cardiology.
[79] U. Tebbe,et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). , 1994, Journal of the American College of Cardiology.
[80] C. Fry,et al. Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.
[81] R. Becker. Thrombolytic retreatment with tissue plasminogen activator for threatened reinfarction and thrombotic coronary reocclusion , 1994, Clinical cardiology.
[82] R. Califf,et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy , 1993, The Lancet.
[83] Gusto Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.
[84] U. Tebbe,et al. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. , 1993, The American journal of cardiology.
[85] B. Keyt,et al. A Slow Clearing, Fibrin-Specific, PAI-1 Resistant Variant of t-PA (T103N, KHRR 296-299 AAAA) , 1993, Thrombosis and Haemostasis.
[86] J. Heim,et al. Thrombolytic and Haemorrhagic Effects of Bolus Doses of Tissue-Type Plasminogen Activator and a Hybrid Plasminogen Activator with Prolonged Plasma Half-Life (K2tu-PA: CGP 42935) , 1993, Thrombosis and Haemostasis.
[87] F. Van de Werf,et al. Coronary Thrombolysis With Recombinant Staphylokinase in Patients With Evolving Myocardial Infarction , 1993, Circulation.
[88] J. Heim,et al. Thrombolytic Activity of Two Chimeric Recombinant Plasminogen Activators (FK2tu-PA and K2tu-PA) in Rabbits , 1992, Thrombosis and Haemostasis.
[89] David Hunt,et al. ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .
[90] R. Califf,et al. Racial Differences in Responses to Thrombolytic Therapy With Recombinant Tissue‐Type Plasminogen Activator: Increased Fibrin(ogen)olysis in Blacks , 1991, Circulation.
[91] H. Hod,et al. Repeat infusion of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia. , 1990, Journal of the American College of Cardiology.
[92] H. White,et al. Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. , 1990, British heart journal.
[93] B. Coller. Platelets and thrombolytic therapy. , 1990, The New England journal of medicine.
[94] U. Tebbe,et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.
[95] S. Sherry. The origin of thrombolytic therapy. , 1989, Journal of the American College of Cardiology.
[96] C. White,et al. INTENSE MICROVASCULAR CONSTRICTION AFTER ANGIOPLASTY OF ACUTE THROMBOTIC CORONARY ARTERIAL LESIONS , 1989, The Lancet.
[97] Aims Trial Study Group. EFFECT OF INTRAVENOUS APSAC ON MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION: PRELIMINARY REPORT OF A PLACEBO-CONTROLLED CLINICAL TRIAL , 1988, The Lancet.
[98] G. Barlow,et al. Comparison of Plasminogen Activators , 1987, Seminars in thrombosis and hemostasis.
[99] Y. Ohtsuki,et al. ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.
[100] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.
[101] F. Sheehan,et al. Intravenous urokinase in acute myocardial infarction. , 1985, The American journal of cardiology.
[102] E. Plow,et al. The presence and release of alpha 2-antiplasmin from human platelets. , 1981, Blood.
[103] M S Golden,et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.
[104] K. Karsch,et al. Acute myocardial infarction: Intracoronary application of nitroglycerin and streptokinase , 1979, Clinical cardiology.
[105] W. Tillett,et al. THE FIBRINOLYTIC ACTIVITY OF HEMOLYTIC STREPTOCOCCI , 1933, The Journal of experimental medicine.
[106] J. Anderson,et al. Why does thrombolysis fail? Breaking through the reperfusion ceiling. , 1997, The American journal of cardiology.
[107] F. Verheugt. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. , 1997, The New England journal of medicine.
[108] Johan Herlitz,et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .
[109] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[110] S. Holmberg. Thrombolysis in acute myocardial infarction. , 1992, British journal of hospital medicine.
[111] R. Rudolph,et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. , 1992, Protein engineering.
[112] A. Mazaev,et al. [Intracoronary administration of fibrinolysin in acute myocardial infarct]. , 1976, Terapevticheskii arkhiv.
[113] Chazov Ei,et al. Intracoronary administration of fibrinolysin in acute myocardial infarct , 1976 .
[114] A. Fletcher,et al. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. , 1958, Transactions of the Association of American Physicians.